# Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection

> **NCT04218513** · PHASE1 · COMPLETED · sponsor: **Nanjing Yoko Biomedical Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Drug-drug Interaction

## Interventions

- **DRUG:** Compound Edaravone Injection
- **DRUG:** Edaravone Injection
- **DRUG:** 2-Aminoethanesulfonic Acid Injection

## Key facts

- **NCT ID:** NCT04218513
- **Lead sponsor:** Nanjing Yoko Biomedical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-10
- **Primary completion:** 2019-05-31
- **Final completion:** 2019-05-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04218513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04218513, "Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04218513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*